Vanguard Group Inc. Buys 1,728,453 Shares of Savara Inc. $SVRA

Vanguard Group Inc. lifted its stake in shares of Savara Inc. (NASDAQ:SVRA) by 20.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,041,647 shares of the company’s stock after purchasing an additional 1,728,453 shares during the quarter. Vanguard Group Inc. owned 4.94% of Savara worth $60,551,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rosalind Advisors Inc. raised its stake in shares of Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after purchasing an additional 1,345,056 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Savara during the 3rd quarter valued at $96,000. The Manufacturers Life Insurance Company raised its stake in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Savara during the 3rd quarter valued at $90,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Savara by 86.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,154 shares of the company’s stock valued at $90,000 after purchasing an additional 11,681 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Savara Price Performance

Shares of Savara stock opened at $5.27 on Friday. The company has a current ratio of 13.47, a quick ratio of 11.85 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.08 billion, a PE ratio of -9.41 and a beta of 0.28. The business’s 50-day moving average price is $5.36 and its 200-day moving average price is $5.48. Savara Inc. has a 12 month low of $1.89 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Sell-side analysts forecast that Savara Inc. will post -0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SVRA has been the topic of a number of analyst reports. William Blair set a $10.00 price objective on Savara in a research note on Monday, March 16th. Oppenheimer started coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. Finally, Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.13.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.